Similarly, ANRIL expression was higher in hepatocellular carcinoma tissues than in adjacent tumor-free tissues, and patients with high ANRIL expression showed significantly poor overall survival.[26] In addition, ANRIL overexpression in patients with serous ovarian cancer was associated with an aggressive tumor phenotype and poor prognosis. Here, CDKN2B-AS1 is linked to neoplasm.